Stenocare A/S provided sales guidance for the year 2023. For the year, the company expects sales to be lower than expected, probably in the range of 7.5 to 10.0 mDKK, which is 167% to 222% of sales in 2022. Stenocare still expects to reach an annual revenue run rate by end of 2023 of 15-20 mDKK which will be an important steppingstone ahead of break-even, which is now expected in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.02 DKK | -1.57% | +0.40% | +97.64% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+97.64% | 1.34Cr | |
+44.36% | 628.72Cr | |
-13.52% | 454.61Cr | |
+10.85% | 326.92Cr | |
-6.52% | 322.86Cr | |
-0.71% | 255.54Cr | |
+51.14% | 200.39Cr | |
-5.22% | 168.32Cr | |
+1.29% | 164.2Cr | |
+57.69% | 160.21Cr |
- Stock Market
- Equities
- STENO Stock
- News Stenocare A/S
- Stenocare A/S Provides Sales Guidance for the Year 2023